Orchid Pharma Limited (BOM:524372)
India · Delayed Price · Currency is INR | Market Cap | 39.17B |
| Revenue (ttm) | 8.50B |
| Net Income (ttm) | 852.17M |
| Shares Out | n/a |
| EPS (ttm) | 16.80 |
| PE Ratio | 45.96 |
| Forward PE | 34.37 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,149 |
| Average Volume | 6,829 |
| Open | 785.15 |
| Previous Close | 785.15 |
| Day's Range | 763.50 - 785.15 |
| 52-Week Range | 603.80 - 1,998.00 |
| Beta | n/a |
| RSI | 56.05 |
| Earnings Date | Aug 12, 2025 |
About Orchid Pharma
Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India. Its active pharmaceutical ingredients product portfolio includes oral cephalosporins, injectable cephalosporins, veterinary products, and non-antibiotics. The company has multi-therapeutic presence in anti-infectives, anti-inflammatory, central nervous system, cardiovascular segment, nutraceuticals, and other oral and sterile product... [Read more]
Financial Performance
In 2024, Orchid Pharma's revenue was 9.22 billion, an increase of 12.52% compared to the previous year's 8.19 billion. Earnings were 996.57 million, an increase of 8.13%.
Financial StatementsNews
Top stocks to buy today: Stock recommendations for July 16, 2025 - check list
Stock market recommendations: Anand Rathi Shares suggests buying Tilak Nagar Industries, Orchid Pharma, and ITC. Tilak Nagar Industries shows range breakout with volume support. Orchid Pharma indicate...
Orchid Pharma shares drop nearly 5% as Q4 net profit falls 32.4% YoY to Rs 22.3 crore
Orchid Pharma witnessed a sharp decline in its stock price, falling nearly 5% following the release of its fourth-quarter results for FY25. As of 10:11 AM, the shares were trading 4.98% lower at Rs 70...
Orchid Pharma shares surge 4.4% after successful USFDA inspection at Alathur API facility
Orchid Pharma Ltd. saw a 4% jump in its stock price following the successful completion of a surprise inspection by the United States Food and Drug Administration (USFDA) at its Active Pharmaceutical ...
Orchid Pharma successfully completes USFDA inspection at Alathur API facility, secures EU GMP certification renewal
Orchid Pharma Limited has announced the successful completion of a surprise USFDA inspection at its Active Pharmaceutical Ingredient (API) manufacturing facility in Alathur, Tamil Nadu. The inspection...
Orchid Pharma shares drop over 14% as net profit falls 25.63% YoY to ₹22.45 crore in Q3
Orchid Pharma witnessed a sharp decline of over 14% in its stock price after the company reported weak financial results for Q3. As of 10:27 AM, the shares were trading 14.78% lower at Rs 1,051.65. Fo...
Orchid Pharma shares jump nearly 4% following strong Q2 FY25 results
Orchid Pharma shares rose by 3.94%, trading at ₹1,509.90 on the NSE as of 11:29 am, driven by impressive Q2 FY25 financial results showcasing robust growth in revenue and profitability. Key Financial ...
Orchid Pharma Q2 FY25 Results: Revenue jumps 12% to ₹222.7 crore, PAT up 26% YoY
Orchid Pharma announced its Q2 FY25 results, reflecting strong growth in revenue and profitability. The company continues to benefit from efficient cost management and operational improvements, leadin...